Drug Therapies for Kidney Cancer

There are many FDA-approved targeted therapies and immunotherapies, as well as combinations that combine both. Your doctor will review your tests, staging and history, and discuss the treatment options that are appropriate for you.

Which drug therapy is right for me?

Below are resources for treatment that may be recommended based on your tumor stage and health status.

ADJUVANT THERAPY

Often given when the patient may be at high risk for a disease recurrence, even after the tumor and/or affected kidney have been surgically removed.

Options for Advanced Kidney Cancer

When kidney cancer has spread to other organs, the cancer is usually not completely curable. The goal of treatment is therefore to make life as long and as normal as possible. Combinations of different treatments may be recommended to control or diminish the cancer.

Options for first line treatments for advanced kidney cancer

What are my choices and how do we select a therapy? Most patients start with a combination of two immunotherapies (IO/IO) or a TKI (tyrosine kinase inhibitor, a targeted cancer therapy) combined with an immunotherapy. Learn more about your options for your first line of treatment with the useful discussions from CURE TODAY.

Targeted therapy and Immune Checkpoint Inhibitors (ICIs) Combinations

Learn more about TKI/Immunotherapy combinations as a first line treatment or in later lines by clicking the link below.

Dual Immunotherapy

Learn more about IO/IO combinations (also called dual immunotherapy or dual checkpoint inhibition) as a first line treatment or in later lines.

Targeted Therapy Drugs

Targeted therapy drugs precisely identify and inhibit certain  cancer cells. A targeted therapy can be used by itself or in combination with other treatments.

Immunotherapy and Immune Checkpoint Inhibitors (ICIs)

An important part of the immune system is its ability to attack pathogens and cancer cells, but ignore healthy normal cells in the body. To do this, it uses “checkpoints,” which are proteins on immune cells that keep them inactivated and need to be disabled to start an immune response. Kidney cancer cells sometimes hijack these checkpoints to evade the immune system. But these drugs disable the checkpoint proteins, helping to reinvigorate the immune response against the cancer cells.

IO/IO also known as Dual checkpoint inhibition

The current standard of care for kidney cancer are combinations of two drugs that have demonstrated greater efficacy than treatment with a single agent. There are multiple FDA approved TKI/IO combinations that your medical oncologist can help explaining the differences and which might be best for your disease.

We currently only have one FDA approved combination of two immunotherapy drugs (IO/IO) but others are being tested in clinical trials.

TKI / IO
Axitinib (Inlyta) + Pembrolizumab (Keytruda)

TKI / IO
Cabozantinib (Cabometyx)+Nivolumab (Opdivo)

TKI / IO
Lenvatinib (Lenvima) +Pembrolizumab (Keytruda)

TKI / IO
Axitinib (Inlyta) + Pembrolizumab (Keytruda)

I had more than one choice as a suggested treatment. How do I get ready to give my input?

IKCC and KidneyCAN patients and their families have an essential role to play in healthcare decisions that affect their lives. The IKCC shared decision aid series is written for people with kidney cancer, their caregivers and families. The booklets are written by a team of patients, patient advocates and medical professionals.

One of my choices was a clinical trial. I want to learn more before I decide.

Clinical trials are research studies that involve people. Any time you or a loved one need treatment for cancer, clinical trials are an option to think about. Learning all you can about clinical trials can help you talk with your doctor and decide what is right for you.

Understanding Your Kidney Cancer Diagnosis

GO TO PAGE

Visit

Building a Care Team

GO TO PAGE

Visit

Treatment & Trial Options

GO TO PAGE

Visit

Living Well with Kidney Cancer

GO TO PAGE

Visit

WHO WE ARE →

WHAT WE DO →

OUR STORIES →

THE KIDNEY CANCER COMMUNITY →

SCIENTIFIC ADVISORS →

DONATE →

CONTACT →

Latest News

Lenny and Phyllis: “We Need to Keep Up the Fight”

Lenny and Phyllis: “We Need to Keep Up the Fight”

Phyllis was diagnosed with kidney cancer in 2012. Tumors were found on both kidneys and treated with surgery. Her cancer progessed to stage IV in 2014, but Phyllis says, "Here I am, ten years later! Life has changed, but it is good!" For this month's Community Spotlight, we are sharing the story...

SPRING ADVOCACY DAYS 2023 →

DISTRICT DAYS 2022 →

JOIN OUR COMMUNITY →

RAISING AWARENESS →

BE AN ADVOCATE →

DONATE NOW →

CONTACT →

Latest News

District Days: Asking Congress to Fund Kidney Cancer Research

District Days: Asking Congress to Fund Kidney Cancer Research

On August 8-9th, KidneyCAN gathered advocates from all over the United States to ask Congress for robust funding for kidney cancer research through the NIH and CDMRP (Congressionally Directed Medical Research Programs). Read on to hear about our goals for this event and how you can help fund...

Patient Resource Center

UNDERSTANDING YOUR KIDNEY CANCER DIAGNOSIS

BUILDING YOUR CARE TEAM

TREATMENT & TRIAL OPTIONS

LIVING WELL WITH KIDNEY CANCER

CLINICAL TRIALS →

IMMUNOTHERAPY →

KCRS: KIDNEY CANCER RESEARCH SUMMIT →

RESEARCH OPPORTUNITIES →

NEWS →

Latest News

The 2022 Kidney Cancer Research Summit

The 2022 Kidney Cancer Research Summit

Dr. Laurence Albiges (Institut Gustave Roussy) presents on the microbiome at KCRS22. The microbiome has now been recognized as one of the emerging hallmarks and enabling characteristics of cancer. KidneyCAN hosted the 4th Annual Kidney Cancer Research Summit on October 6-7, 2022  live in...

SUPPORT OUR WORK →

FUNDRAISE FOR KIDNEYCAN →

DONATE →

CONTACT →

Latest News

Lenny and Phyllis: “We Need to Keep Up the Fight”

Lenny and Phyllis: “We Need to Keep Up the Fight”

Phyllis was diagnosed with kidney cancer in 2012. Tumors were found on both kidneys and treated with surgery. Her cancer progessed to stage IV in 2014, but Phyllis says, "Here I am, ten years later! Life has changed, but it is good!" For this month's Community Spotlight, we are sharing the story...